The Clinical Characteristics of Pedigrees of Leber's Hereditary Optic Neuropathy With the 11778 Mutation

https://doi.org/10.1016/S0002-9394(14)76784-4Get rights and content

In a study of the phenotypic characteristics of pedigrees of Leber's hereditary optic neuropathy positive for the mitochondrial DNA mutation at position 11778, 28 of 49 pedigrees were represented by singleton cases. Seven families, including six singleton pedigrees, had maternal family members with a mixture of mutant and normal mitochondrial DNA (heteroplasmy). Seventy-two affected individuals from 43 families showed a male predominance of 81.9% (59/72) and ages of onset of visual loss ranging from 8 to 60 years. The time interval between affected eyes averaged 1.8 months; the duration of progression of visual loss in each eye averaged 3.7 months. Visual acuity was 20/200 or worse in 107 of 109 (98.2%) eyes. Telangiectatic microangiopathy, disk pseudoedema, or vascular tortuosity, ophthalmoscopic features believed to be classic of Leber's hereditary optic neuropathy, were noted in 30 of 52 patients. Visual-evoked responses were typically absent or abnormal. Electrocardiograms, fluorescein angiograms, cerebrospinal fluid analyses, brain computed tomography, and magnetic resonance imaging were usually normal. There were no consistent neurologic or systemic illnesses associated with these Leber's pedigrees. In many cases, the diagnosis would not have been suspected because of the absence of a compatible family history, typical clinical profile, or ophthalmoscopic appearance. Genetic analysis showed the mitochondrial DNA mutation at position 11778, which established the diagnosis of Leber's hereditary optic neuropathy and has allowed for a broader view of the clinical features of this disease.

References (49)

  • E.M. Stone et al.

    Mae III positively detects the mitochondrial mutation associated with type I Leber's hereditary optic neuropathy

    Arch. Ophthalmol

    (1990)
  • M.A. Morris

    Mitochondrial mutations in neuro-ophthalmological diseases. A review

    J. Clin. Neuro-Ophthalmol

    (1990)
  • D.R. Johns

    Improved molecular-genetic diagnosis of Leber's hereditary optic neuropathy

    N. Engl. J. Med.

    (1990)
  • J.L. Smith et al.

    Optic nerve sheath distention in Leber's optic neuropathy and the significance of the “Wallace mutation.”

    J. Clin. Neuro-Ophthalmol

    (1990)
  • D.R. Johns

    The molecular genetics of Leber's hereditary optic neuropathy

    Arch. Ophthalmol

    (1990)
  • J.M. Shoffner et al.

    Oxidative phosphorylation diseases. Disorders of two genomes

    Adv. Hum. Genet.

    (1990)
  • J. Vilkki et al.

    Segregation of mitochondrial genomes in a heteroplasmic lineage with Leber hereditary optic neuroretinopathy

    Am. J. Hum. Genet.

    (1990)
  • F.M. Ausubel et al.
  • E.K. Nikoskelainen et al.

    Leber's hereditary optic neuroretinopathy, a maternally inherited disease. A genealogic study in four pedigrees

    Arch. Ophthalmol

    (1987)
  • E. Nikoskelainen et al.

    The early phase in Leber hereditary optic atrophy

    Arch. Ophthalmol

    (1977)
  • E. Nikoskelainen et al.

    Pre-excitation syndrome and Leber's hereditary optic neuroretinopathy

    Lancet

    (1985)
  • E. Nikoskelainen et al.

    Ophthalmoscopic findings in Leber's hereditary optic neuropathy. II. The fundus findings in the affected family members

    Arch. Ophthalmol

    (1983)
  • E. Nikoskelainen et al.

    Fundus findings in hereditary optic neuroretinopathy. III. Fluorescein angiographic studies

    Arch. Ophthalmol

    (1984)
  • J.-D. Chen et al.

    Preliminary exclusion of an X-linked gene in Leber optic atrophy by linkage analysis

    Hum. Genet.

    (1989)
  • Cited by (382)

    • Retinitis pigmentosa with optic neuropathy and COQ2 mutations: A case report

      2022, American Journal of Ophthalmology Case Reports
    View all citing articles on Scopus

    This study was supported in part by a departmental grant from Research to Prevent Blindness, Inc. (Dr. Newman); by National Institutes of Health grant N521328 and a Muscular Dystrophy Clinical Research grant (Dr. Wallace); and by the Clinical Research Center of Emory University School of Medicine, supported by National Institutes of Health grant M01-RR-00039. This study was presented in part at the International Neuro-Ophthalmology Symposium in Winchester, England, June 27, 1990.

    Reprint requests to Nancy J. Newman, M.D., NeuroOphthalmology Unit, Emory Eye Center, 1327 Clifton Rd. N.E., Atlanta, GA 30322.

    View full text